Navigation Links
Surgery improves quality of life for children with sleep apnea
Date:2/12/2008

of postoperative follow up, especially for children who had severe OSA.

Even though OSA resolved in the overwhelming majority of children after the surgery, it is still crucial to identify and treat children with persistent OSA, Mitchell says. Otherwise these children will continue to experience the health, behavioral and learning problems associated with OSA.

Several options for treating persistent OSA exist, including: nasal steroids, allergy treatment, additional surgery or continuous positive airway pressure (CPAP) mask. Over time, some children who did not experience immediate resolution will normalize, Mitchell says. Children who are overweight must lose weight in conjunction with the surgery for a successful outcome.

Obese children and children with Downs syndrome or other genetic disorders that affect the craniofacial anatomy were excluded from the study because the rate of OSA is known to be higher.


'/>"/>

Contact: Sara Savat
ssavat@slu.edu
314-977-8018
Saint Louis University
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. One Surgery Often Enough for Peritonitis
2. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
3. Surgery for severe obesity saves lives
4. Some Epilepsy Patients Are Good Candidates for Surgery
5. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
6. Hypnosis Eases Pain of Breast Cancer Surgery
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. Minimally Invasive Heart Surgery Research Wins N.I.H. Award
9. Cosmetic Surgery & Exotic Brazil
10. Small Incisions Make Heart Valve Surgery Safer
11. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...en long-term side effects, study finds , ...otherapy alone, and delaying or avoiding radiation... with inoperable or progressive low-grade glioma b...udy. , Low-grade glioma is the most common brai...the survival rate for patients is 95 percent. But ...
(Date:10/10/2008)...cientists have identified a protein that plays mat..., T and B cells, enabling them to interact in a wa...unity after an infection. Their finding may also ...fect that prevents them from making this proteinca...n virus that otherwise is rarely fatal (Epstein-Ba...
(Date:10/10/2008)...ire-FirstCall/ -- Accuray,Incorporated (Nasdaq: A...y,today announced that it will report results for...ber 27, 2008, on Wednesday, October 29, 2008 after...the results will begin at 2:00 p.m. PDT,(5:00 p.m...., president and,chief executive officer and Holly ...
(Date:10/9/2008)...ive Accredited Course for,Non-Dermatologists about... November 1, 2008 at the Royal Sonesta Hotel Bosto...ire-USNewswire/ -- The Melanoma,Foundation of New ...ne are,co-sponsoring an Accreditation Council for ...ate non-dermatologists on the detection and manage...
Breaking Medicine News(10 mins):Health News:Chemo Alone Effective in Treating Kids' Brain Tumors 2Health News:NIH scientists discover crucial control in long-lasting immunity 2Health News:NIH scientists discover crucial control in long-lasting immunity 3Health News:Accuray Incorporated to Report First Quarter Fiscal Year 2009 Financial Results 2Health News:Paul Sullivan's Legacy: An Early Warning Program for Detecting Melanoma Before It's Too Late 2
...ealth Organisation experts visioned Australians ar...tries // . When addressing in National Medicines ...ustralia has got the best systems all over the wor...vative medicines. Dr Laing's words that triggers ...
...desparities among governments both state and feder...ed for mental health services need to be squandere...revious approaches it was clear that both were hav... The former competition regulator, Professor Hicki...
...k of a vine is thought to possess properties very ...f diabetics and the obese // . This discovery has ...an is the former federal health minister Michael W...s yet to apply for a patent, so your guess is as g...
...ng to the Royal College of GPs they plan to introd... Michelin-style rating system // . They are asking...e of grading but ministers and the British Medical...is the surgeries were to be inspected by doctors, ...
Other Medicine News:
(Date:10/8/2008)..., France, Oct. 8 /- Vical Incorporate...inical data and new nonclinical data,demonstrating...roadly,applicable in DNA- and protein-based infect...cines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,... present the data today,Wednesday, October 8, at ...
(Date:10/7/2008)...aluates the efficacy of new device for detecting p...ing colonoscopy, ORLANDO, Fla., Oct. 7 /PRNewswir...Annual Scientific Meeting in Orlando (ACG 2008), r...ented results from a,multi-institutional clinical ...(R) Retroscope(R), a new device that is designed t...
(Date:10/7/2008)...Showed Larazotide Acetate Prevented Immunologic Ch...s with Celiac Disease, Additional Data Indicates P...ORLANDO, Fla., Oct. 7 /- Alba Therape...cal studies this week at the American,College of G...ng. Data from,study CLIN 1001-004, the first Phase...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Scientific M...Call/ -- Ironwood,Pharmaceuticals, Inc. (formerly ...E: FRX ) today announced the presentation of resu...safety and efficacy in 420 patients with,irritable...s of the data,indicates that once- daily oral dosi...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5AMERIGROUP Corporation to Host Investor Day 1320 1AMERIGROUP Corporation to Host Investor Day 1320 2Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes 1317 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 2Monsanto Company Signs Share Subscription Agreement With Devgen 594 3Non Stick Gum Something to Chew On 1313 1
...l pH.p Capsule passes through the GI tract, it tra...cies to the SmartPill Data Receiver, a small, ligh...he patient (supported by either a belt or lanyard)...mperature and pH measurement data, and elapsed and...
For the quantitative determination of human MMP-9/NGAL Complex concentrations in cell culture supernates, serum,plasma, urine and saliva.
...copic cases it is extremely popular to combine a F...his combination affords the surgeon optimal viewin...ortable pose. The Dual Light System has the capab... such the light can be purchased separately and th...
...copic cases, it is extremely popular to combine a ...This combination affords the surgeon optimal viewi...fortable pose. The Single Light System has the ca... As such the light can be purchased separately and...
Medicine Products: